Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 6Phase 1/2 3Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 6INDUSTRY 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × entinostat × Clear all
NCT07261592 2025-12-03

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Not yet recruiting
29 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Indiana University

Phase 1/2 Terminated
31 enrolled 19 charts
Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

NCT03838042 2024-02-07

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

University Hospital Heidelberg

Phase 1/2 Recruiting
91 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡